Head and Neck Cancers
Experts Make the Case for Buprenorphine Use in Cancer-Related Pain Management
June 28, 2022
Article
Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
Avasopasem Represents Potential Mitigation Strategy for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer
June 04, 2022
Article
Avasopasem was associated with a significant reduction in severe oral mucositis in patients with locally nonmetastatic head and neck cancer undergoing chemoradiotherapy.
The Basics of Biosimilars for Oncology Nurses
June 03, 2022
Article
Kellie Zeichner, RN, BSN, OCN, discusses the production of biosimilars, their approval and naming processes, and why immunogenicity is important when discussing these agents.
Tislelizumab/Chemo Combo Extends Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Cancer
April 24, 2022
Article
The phase 3 RATIONALE 309 trial highlighted the combined efficacy of tislelizumab and chemotherapy in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent/Metastatic Head and Neck Cancer
April 01, 2022
Article
A post-hoc efficacy analysis of KEYNOTE-048 found that CPS scores were linked to immunotherapy efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
FDA Approves Additional Cetuximab Dose for KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck Cancer
April 07, 2021
Article
The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
Tipifarnib Promising in Relapsed/Metastatic HRAS-Mutant HNSCC
March 27, 2021
Article
Tipifarnib showed promising clinical activity in patients with recurrent and/or metastatic, HRAS-mutant head and neck squamous cell carcinoma whose disease had progressed after prior therapy.
Tipifarnib Gets Breakthrough Therapy Designation for HRAS-Mutated HNSCC
February 25, 2021
Article
The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.
Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal Cancers
August 13, 2020
Article
Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
FDA Expands Gardasil 9 Approval for HPV-Related Cancers
June 15, 2020
Article
On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.